Literature DB >> 21810974

In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer.

B Cosci1, A Vivaldi, C Romei, F Gemignani, S Landi, R Ciampi, A Tacito, E Molinaro, L Agate, V Bottici, V Cappagli, D Viola, P Piaggi, P Vitti, A Pinchera, R Elisei.   

Abstract

Germline and somatic RET oncogene mutations are found in 98% hereditary and 40% sporadic medullary thyroid carcinomas. Our aim was to analyse by in silico and in vitro assays the transforming activity of six rare RET mutations (T338I, V648I, M918V, A883T, S904F and M848T). Six known RET mutations were used as controls. The in silico analysis showed the highest score value (i.e. 65) for S904F, M848T, M918T and C634R, whereas L790F, G691S, T338I and V648I had 0 score. Intermediate score values were obtained by A883T (score=55), M918V, V804M and Y791F (score=15). The in vitro focus formation assay showed that cells transfected with S904F, M918T, M848T or C634R generated the largest number of focus formation units (FFU). Intermediate numbers of FFU were observed in cells transfected with M918V, V804M, Y791F or A883T, while cells transfected with L790F, G691S, T338I or V648I showed a number of FFU similar to control cells. A positive correlation between the in silico score and in vitro FFU was found (P=0.0005). Only cells transfected with M918T or C634R grew faster and generated higher number of colonies in soft agar than control cells. However, the cells that were transfected with V804M produced an intermediate number of colonies. In conclusion, two of the six rare RET mutations, S904F and M848T possessed a relatively high transforming activity but a low aggressiveness; the other four mutations T338I, V648I, M918V and A883T were low or non-transforming, and their ability to induce tumoural transformation might be related to particular genetic conditions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21810974     DOI: 10.1530/ERC-11-0117

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  19 in total

Review 1.  Management of hereditary medullary thyroid carcinoma.

Authors:  Theodora Pappa; Maria Alevizaki
Journal:  Endocrine       Date:  2016-02-02       Impact factor: 3.633

Review 2.  RET revisited: expanding the oncogenic portfolio.

Authors:  Lois M Mulligan
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

3.  The RET E616Q Variant is a Gain of Function Mutation Present in a Family with Features of Multiple Endocrine Neoplasia 2A.

Authors:  William Grey; Rosaline Hulse; Anna Yakovleva; Dilyana Genkova; Benjamin Whitelaw; Ellen Solomon; Salvador J Diaz-Cano; Louise Izatt
Journal:  Endocr Pathol       Date:  2017-03       Impact factor: 3.943

4.  2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer.

Authors:  R Elisei; M Alevizaki; B Conte-Devolx; K Frank-Raue; V Leite; G R Williams
Journal:  Eur Thyroid J       Date:  2012-12-19

5.  Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland.

Authors:  R Ciampi; C Romei; L Pieruzzi; A Tacito; E Molinaro; L Agate; V Bottici; F Casella; C Ugolini; G Materazzi; F Basolo; R Elisei
Journal:  J Endocrinol Invest       Date:  2016-08-17       Impact factor: 4.256

Review 6.  A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.

Authors:  Cristina Romei; Raffaele Ciampi; Rossella Elisei
Journal:  Nat Rev Endocrinol       Date:  2016-02-12       Impact factor: 43.330

7.  Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility.

Authors:  Rodrigo A Toledo; Roxanne Hatakana; Delmar M Lourenço; Susan C Lindsey; Cleber P Camacho; Marcio Almeida; José V Lima; Tomoko Sekiya; Elena Garralda; Michel S Naslavsky; Guilherme L Yamamoto; Monize Lazar; Osorio Meirelles; Tiago J P Sobreira; Maria Lucia Lebrao; Yeda A O Duarte; John Blangero; Mayana Zatz; Janete M Cerutti; Rui M B Maciel; Sergio P A Toledo
Journal:  Endocr Relat Cancer       Date:  2014-11-25       Impact factor: 5.678

8.  Genetic and clinical features of multiple endocrine neoplasia types 1 and 2.

Authors:  C Romei; E Pardi; F Cetani; R Elisei
Journal:  J Oncol       Date:  2012-11-08       Impact factor: 4.375

Review 9.  A differential diagnosis of inherited endocrine tumors and their tumor counterparts.

Authors:  Sergio P A Toledo; Delmar M Lourenço; Rodrigo A Toledo
Journal:  Clinics (Sao Paulo)       Date:  2013-07       Impact factor: 2.365

10.  AKT1 and BRAF mutations in pediatric aggressive fibromatosis.

Authors:  Cristina Meazza; Antonino Belfiore; Adele Busico; Giulio Settanni; Nicholas Paielli; Luca Cesana; Andrea Ferrari; Stefano Chiaravalli; Maura Massimino; Alessandro Gronchi; Chiara Colombo; Silvana Pilotti; Federica Perrone
Journal:  Cancer Med       Date:  2016-04-08       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.